DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study

References

• Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008; 10:16; PMID:18485221; http://dx.doi.org/10.1186/bcr2098
   Web of Science ®Google Scholar
• Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 2009; 19:165-71; PMID:19429480; http://dx.doi.org/10.1016/j.semcancer.2009.02.007
   PubMed Web of Science ®Google Scholar
• Saxena A, Dhillon VS, Shahid M, Khalil HS, Rani M, Prasad DT, Hedau S, Hussain A, Naqvi RA, Deo SV, et al. GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients. Exp Ther Med 2012; 4:1097-103; PMID:23226781; http://dx.doi.org/10.3892/etm.2012.710
   PubMed Web of Science ®Google Scholar
• Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol 2010; 4:242-54; PMID:20627830; http://dx.doi.org/10.1016/j.molonc.2010.04.002
   PubMed Web of Science ®Google Scholar
• Chen KM, Stephen JK, Raju U, Worsham MJ. Delineating an epigenetic continuum for initiation, transformation and progression to breast cancer. Cancers 2011; 3:1580-92; PMID:21776373; http://dx.doi.org/10.3390/cancers3021580
   PubMedGoogle Scholar
• Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008; 659:40-8; PMID:18407786; http://dx.doi.org/10.1016/j.mrrev.2008.02.004
   PubMed Web of Science ®Google Scholar
• Lodygin D, Hermeking H. The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res 2005; 15:237-46; PMID:15857578; http://dx.doi.org/10.1038/sj.cr.7290292
   PubMed Web of Science ®Google Scholar
• McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15:3927-37; PMID:19509173; http://dx.doi.org/10.1158/1078-0432.CCR-08-2784
   PubMed Web of Science ®Google Scholar
• Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Jr., Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 2012; 12:1471-2407; PMID:22695491; http://dx.doi.org/10.1186/1471-2407-12-243
   Web of Science ®Google Scholar
• Kajabova V, Smolkova B, Zmetakova I, Sebova K, Krivulcik T, Bella V, Kajo K, Machalekova K, Fridrichova I. RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients. Transl Oncol 2013; 6:297-304; PMID:23730409; http://dx.doi.org/10.1593/tlo.13244
   PubMed Web of Science ®Google Scholar
• Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, Latif F. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 2011; 71:2988-99; PMID:21363912; http://dx.doi.org/10.1158/0008-5472.CAN-10-4026
   PubMed Web of Science ®Google Scholar
• Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird PW, Widschwendter M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 2006; 66:29-33; PMID:16397211; http://dx.doi.org/10.1158/0008-5472.CAN-05-2508
   PubMed Web of Science ®Google Scholar
• Marzese DM, Hoon DSB, Chong KK, Gago FE, Orozco JI, Tello OM, Vargas-Roig LM, Roqué M. DNA methylation index and methylation profile of invasive ductal breast tumors. J Mol Diagn 2012; 14:613-22; PMID:22925694; http://dx.doi.org/10.1016/j.jmoldx.2012.07.001
   PubMed Web of Science ®Google Scholar
• Tao MH, Shields PG, Nie J, Millen A, Ambrosone CB, Edge SB, Krishnan SS, Marian C, Xie B, Winston J, et al. DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 2009; 114:559-68; PMID:18463976; http://dx.doi.org/10.1007/s10549-008-0028-z
   PubMed Web of Science ®Google Scholar
• Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuasen RG, Touleimat N, Busato F, Tost J, et al. Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy. Int J Cancer 2014; 135:2085-95; PMID:24658971; http://dx.doi.org/10.1002/ijc.28862
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Maeda I, Oikawa R, Wu W, Tsuchiya K, Miyoshi Y, Itoh F, Tsugawa K, Ohta T. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. Genes Cells 2013; 18:1120-30; PMID:24581343; http://dx.doi.org/10.1111/gtc.12100
   PubMed Web of Science ®Google Scholar
• Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, et al. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol 2014; 73:771-8; PMID:24526178; http://dx.doi.org/10.1007/s00280-014-2404-1
   PubMed Web of Science ®Google Scholar
• Ghosh S, Gu F, Wang CM, Lin CL, Liu J, Wang H, Ravdin P, Hu Y, Huang TH, Li R. Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1. Breast Cancer Res Treat 2014; 147:653-9; PMID:25234841; http://dx.doi.org/10.1007/s10549-014-3132-2
   PubMed Web of Science ®Google Scholar
• Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC, Jr., Yu Y. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 2010; 10:1471-2407; PMID:20642860; http://dx.doi.org/10.1186/1471-2407-10-378
   Web of Science ®Google Scholar
• Jeong YJ, Jeong HY, Lee SM, Bong JG, Park SH, Oh HK. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients. Oncol Rep 2013; 30:2270-8; PMID:23969757; http://dx.doi.org/10.1593/tlo.09148
   PubMed Web of Science ®Google Scholar
• Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lonning PE, Solvang H, Borresen-Dale AL, Tost J, et al. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 2013; 13:1471-2407; PMID:24093668; http://dx.doi.org/10.1186/1471-2407-13-456
   Web of Science ®Google Scholar
• Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011; 458:73-84; PMID:21120523; http://dx.doi.org/10.1007/s00428-010-1013-6
   PubMed Web of Science ®Google Scholar
• Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA, et al. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathological features and survival. Breast Cancer Res 2014; 16:450; PMID:25287138; http://dx.doi.org/10.1186/s13058-014-0450-6
   PubMed Web of Science ®Google Scholar
• Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9:R57; PMID:17764565; http://dx.doi.org/10.1186/bcr1762
   PubMed Web of Science ®Google Scholar
• Dai D, Dong XH, Cheng ST, Zhu G, Guo XL. Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis. Tumour Biol 2014; 35:8209-16; PMID:24850174; http://dx.doi.org/10.1007/s13277-014-2055-1
   PubMed Web of Science ®Google Scholar
• Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brunner N, Schmitt M, Lesche R, Maier S, Timmermans M, et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110:317-26; PMID:17874182; http://dx.doi.org/10.1007/s10549-007-9724-3
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liu H, Sahin A, Dai JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 2005; 113:654-9; PMID:15455373; http://dx.doi.org/10.1002/ijc.20628
   PubMed Web of Science ®Google Scholar
• Blancato J, Graves A, Rashidi B, Moroni M, Tchobe L, Ozdemirli M, Kallakury B, Makambi KH, Marian C, Mueller SC. SYK allelic loss and the role of Syk-regulated genes in breast cancer survival. PLoS One 2014; 9:e87610; PMID:24523870; http://dx.doi.org/10.1371/journal.pone.0087610
   PubMedGoogle Scholar
• Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005; 65:4101-17; PMID:15899800; http://dx.doi.org/10.1158/0008-5472.CAN-05-0064
   PubMed Web of Science ®Google Scholar
• Raish M, Dhillon VS, Ahmad A, Ansari MA, Mudassar S, Shahid M, Batra V, Gupta P, Das BC, Shukla N, et al. Promoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern India. Transl Oncol 2009; 2:264-70; PMID:19956388; http://dx.doi.org/10.1593/tlo.09148
   PubMed Web of Science ®Google Scholar
• Zaki SM, Abdel-Azeez HA, El Nagar MR, Metwally KA, MM SA. Analysis of FHIT Gene Methylation in Egyptian Breast Cancer Women: Association with Clinicopathological Features. Asian Pac J Cancer Prev 2015; 16:1235-9; PMID:25735361; http://dx.doi.org/10.7314/APJCP.2015.16.3.1235
   PubMedGoogle Scholar
• Syeed N, Husain SA, Sameer AS, Chowdhri NA, Siddiqi MA. Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir. Mutat Res 2011; 707:1-8; PMID:21095196; http://dx.doi.org/10.1016/j.mrfmmm.2010.11.001
   PubMed Web of Science ®Google Scholar
• Li Q, Wei W, Jiang YI, Yang H, Liu J. Promoter methylation and expression changes of in cancerous tissues of patients with sporadic breast cancer. Oncology letters 2015; 9:1807-13; PMID:25789047; http://dx.doi.org/10.3892/ol.2015.2908
   PubMed Web of Science ®Google Scholar
• Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM, Hou MF. Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PLoS One 2013; 8:6; PMID:23405268; http://dx.doi.org/10.1371/journal.pone.0056256
   Web of Science ®Google Scholar
• Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P. DNA methylation of RASSF1A, HIN-1, RAR-β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107:970-5; PMID:14601057; http://dx.doi.org/10.1002/ijc.11508
   PubMed Web of Science ®Google Scholar
• Li S, Rong M, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 2006; 237:272-80; PMID:16029926; http://dx.doi.org/10.1016/j.canlet.2005.06.011
   PubMed Web of Science ®Google Scholar
• Xu X, Gammon MD, Jefferson E, Zhang Y, Cho YH, Wetmur JG, Teitelbaum SL, Bradshaw PT, Terry MB, Garbowski G, et al. The influence of one-carbon metabolism on gene promoter methylation in a population-based breast cancer study. Epigenetics 2011; 6:1276-83; PMID:22048254; http://dx.doi.org/10.4161/epi.6.11.17744
   PubMed Web of Science ®Google Scholar
• Verschuur-Maes AH, de Bruin PC, van Diest PJ. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Res Treat 2012; 136:705-15; PMID:23104224; http://dx.doi.org/10.1007/s10549-012-2301-4
   PubMed Web of Science ®Google Scholar
• Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevic N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, et al. Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. Cancer Biomark 2012; 11:75-88; PMID:23011154; http://dx.doi.org/10.3233/CBM-2012-0266
   PubMed Web of Science ®Google Scholar
• Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S, Kwabi-Addo B. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One 2012; 7:31; PMID:22701537; http://dx.doi.org/10.1371/journal.pone.0037928
   Web of Science ®Google Scholar
• Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 2006; 100:169-76; PMID:16791478; http://dx.doi.org/10.1007/s10549-006-9241-9
   PubMed Web of Science ®Google Scholar
• Miyake T, Nakayama T, Kagara N, Yamamoto N, Nakamura Y, Otani Y, Uji K, Naoi Y, Shimoda M, Maruyama N, et al. Association of GSTP1 Methylation with Aggressive Phenotype in ER-positive Breast Cancer. Anticancer Res 2013; 33:5617-23; PMID:24324107
   PubMed Web of Science ®Google Scholar
• Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, Gonzalez K, Xu X, Bradshaw PT, Teitelbaum SL, Garbowski G, et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat 2012; 131:197-205; PMID:21837480; http://dx.doi.org/10.1007/s10549-011-1712-y
   PubMed Web of Science ®Google Scholar
• Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, Ralhan R. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 2010; 87:83-91; PMID:20470789; http://dx.doi.org/10.1016/j.lfs.2010.05.001
   PubMed Web of Science ®Google Scholar
• Alnaes GI, Ronneberg JA, Kristensen VN, Tost J. Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer. Genes 2015; 6:878-900; PMID:26393654; http://dx.doi.org/10.3390/genes6030878
   PubMed Web of Science ®Google Scholar
• Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012; 118:4201-11; PMID:22294349; http://dx.doi.org/10.1002/cncr.27392
   PubMed Web of Science ®Google Scholar
• Han D, Nie J, Bonner MR, McCann SE, Muti P, Trevisan M, Ramirez-Marrero FA, Vito D, Freudenheim JL. Lifetime adult weight gain, central adiposity, and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study. Int J Cancer 2006; 119:2931-7; PMID:17016824; http://dx.doi.org/10.1002/ijc.22236
   PubMed Web of Science ®Google Scholar
• Johnson KC, Koestler DC, Fleischer T, Chen P, Jenson EG, Marotti JD, Onega T, Kristensen VN, Christensen BC. DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. Clin Epigenetics 2015; 7:015-0094; PMID:26213588; http://dx.doi.org/10.1186/s13148-015-0094-0
   Google Scholar
• Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Borresen-Dale AL, Kristensen VN, et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 2010; 12:7; PMID:20056007; http://dx.doi.org/10.1186/bcr2466
   Web of Science ®Google Scholar
• Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Goerlitz DS, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 2011; 22:965-75; PMID:21516318; http://dx.doi.org/10.1007/s10552-011-9769-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL. Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res 2009; 7:634-44; PMID:19435818; http://dx.doi.org/10.1158/1541-7786.MCR-08-0371
   PubMed Web of Science ®Google Scholar
• Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2:2265-75; PMID:17853883; http://dx.doi.org/10.1038/nprot.2007.314
   PubMed Web of Science ®Google Scholar
• Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More? J Natl Cancer Institute 2014; 106:1-11; PMID:25118203; http://dx.doi.org/10.1093/jnci/dju165.
   Google Scholar
• Moelans CB, Verschuur-Maes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011; 225:222-31; PMID:21710692; http://dx.doi.org/10.1002/path.2930
   PubMed Web of Science ®Google Scholar
• Coopman PJP, Do MTH, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000; 406:742-7; PMID:10963601; http://dx.doi.org/10.1038/35021086
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liu H, Sahin A, Dai JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 2005; 113:654-9; PMID:15455373; http://dx.doi.org/10.1002/ijc.20628
   PubMed Web of Science ®Google Scholar
• Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol 2004; 68:1187-97; PMID:15313416; http://dx.doi.org/10.1016/j.bcp.2004.04.030
   PubMed Web of Science ®Google Scholar
• Chavez-Munoz C, Hartwell R, Jalili RB, Jafarnejad SM, Lai A, Nabai L, Ghaffari A, Hojabrpour P, Kanaan N, Duronio V, et al. SPARC/SFN interaction, suppresses type I collagen in dermal fibroblasts. J Cell Biochem 2012; 113:2622-32; PMID:22422640; http://dx.doi.org/10.1002/jcb.24137
   PubMed Web of Science ®Google Scholar
• Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of Stratifin, ERα and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem 2010; 43:380-6; PMID:19961842; http://dx.doi.org/10.1016/j.clinbiochem.2009.11.016
   PubMed Web of Science ®Google Scholar
• Steiner M, Clark B, Tang J-Z, Zhu T, Lobie PE. Fourteen-3-3σ mediates G2–M arrest produced by 5-aza-2′-deoxycytidine and possesses a tumor suppressor role in endometrial carcinoma cells. Gynecologic Oncol 2012; 127:231-40; PMID:22772061; http://dx.doi.org/10.1016/j.ygyno.2012.06.039
   PubMed Web of Science ®Google Scholar